Stockholders’ Equity (Details Narrative) - USD ($)				12 Months Ended
	Sep. 11, 2023	Aug. 25, 2022	Aug. 02, 2022	Dec. 31, 2023
Subsidiary, Sale of Stock [Line Items]
Proceeds from Issuance or Sale of Equity	$ 5,000,000		$ 3,500,000
Aggregate shares issued	65,790
Fair market value	$ 263,160
Consulting expense				$ 26,600
Reverse stock split		one-for-ten
Private Placement [Member]
Subsidiary, Sale of Stock [Line Items]
Issuance of shares	1,250,000		2,500,000
Share price	$ 4.00		$ 1.40
Employment Agreement [Member]
Subsidiary, Sale of Stock [Line Items]
Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Aggregate Intrinsic Value, Outstanding				3,580,000
Employee Benefits and Share-Based Compensation				$ 1,320,500
Agreement, Description				To the extent the Company has not established an employee equity compensation plan on or prior to August 18, 2024, the restricted shares may be converted, at the election of the executive, in full or in part, into cash compensation, at a rate of $3.58 per share of common stock, which was the fair market value of the common stock on October 10, 2023, which was the date the Board of Directors approved the Grant.. Since the issuance of the restricted stock can be settled in cash, the monthly amortization of the $3,580,000 fair value of the restricted stock grant is recorded as stock compensation payable.
Restricted Stock [Member] | Employment Agreement [Member]
Subsidiary, Sale of Stock [Line Items]
Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period				1,000,000